AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03740971
Drug: Guideline-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based therapy
Trial: NCT02911701
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00910221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT03263507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline .9%
Trial: NCT02504333
Drug: m-FOLFOX
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 28 according to the dose levels stablished in Phase I
Trial: NCT03222206
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Medicate salsalate 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month
Trial: NCT00827021
Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 IU/week I.V. Until the end of the trial
Trial: NCT00827021
Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18000 IU/week I.V. Until the end of the trial
Trial: NCT04676997
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
Trial: NCT00964327
Drug: TMC114
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01208714
Drug: Optimal medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c \< 6.5%).
Trial: NCT01040455
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily for eight weeks
Trial: NCT04342975
Drug: Nicotinamide Riboside + Pterostilbene
RxNorm normalized name: nicotinamide ribotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 2 capsules of Basis™ (each capsule 250 mg of NR and 50 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
Trial: NCT04342975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The correspondent placebo will be administered in a regimen of 2 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
Trial: NCT00631748
Drug: Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
Trial: NCT00741780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04489641
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological intervention
Trial: NCT01983969
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by vein or mouth three times a day from Day -1.
Trial: NCT00939900
Drug: zoledronic acid (aclasta)
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
Trial: NCT01258907
Drug: MLDL1278A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose
Trial: NCT01258907
Drug: MLDL1278A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating intravenous dose
Trial: NCT02709018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01258907
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating intravenous dose
Trial: NCT01258907
Drug: statin, stable dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating oral dose
Trial: NCT00711386
Drug: GSK706769
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg, 100mg, 200mg, or 400mg
Trial: NCT01054742
Drug: Standard of Care PegIntron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
Trial: NCT03138538
Drug: Part 1: M8891
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
Trial: NCT00290615
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00879229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ambrisentan administered orally once daily.
Trial: NCT00836576
Drug: Lotensin® 40 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 40 mg, single-dose fasting
Trial: NCT01240642
Drug: ASA404
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03615105
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg IV
Trial: NCT04564053
Drug: LNA043
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection on Day 1
Trial: NCT04564053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection on Day 1
Trial: NCT00303628
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00303628
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01367145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules placebo per day
Trial: NCT04623242
Drug: Matching Placebo (Gantenerumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of placebo every 4 weeks
Trial: NCT04623242
Drug: Matching Placebo (Solanezumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of placebo every 4 weeks
Trial: NCT00278421
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00278421
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00019409
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00019409
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00019409
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00019409
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01414257
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
Trial: NCT02823977
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded comparator administered to control arm
Trial: NCT03733223
Drug: Ateptidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of ischemic stroke with Ateptidase
Trial: NCT00115154
Drug: Aldara (imiquimod) cream, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02387359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03238781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
Trial: NCT03175900
Drug: Naoan dripping pills
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）
Trial: NCT03175900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)
Trial: NCT00092222
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
Trial: NCT00092222
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
Trial: NCT00607308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo IV on Day 1
Trial: NCT02572713
Drug: DaTSCAN™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02452190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01117636
Drug: Acetylsalicylic acid (Fast release Aspirin, BAY1019036)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter \[mL\]) between 14 hours post dental surgery.
Trial: NCT01117636
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
Trial: NCT01117636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
Trial: NCT00193115
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00193115
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00847912
Drug: Placebo, vehicle control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped.
Trial: NCT03047070
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV normal saline infusion
Trial: NCT00092222
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide: if CD4 \< 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 greater than or equal to 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
Trial: NCT02642653
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once per day dosing
Trial: NCT01211249
Drug: GLPG0259 oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
Trial: NCT03434405
Drug: Psychotropic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual delivered by patient's practitioner
Trial: NCT01211249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
Trial: NCT01211249
Drug: Placebo (Part B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
Trial: NCT02597660
Drug: Bacteriostatic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, the diluent used to reconstitute somatropin
Trial: NCT04044131
Drug: Sorbitol
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
Trial: NCT01317589
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%
Trial: NCT02378935
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily with food
Trial: NCT01375920
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a matched placebo will be administered to patients to take twice a day for 3 weeks
Trial: NCT02674880
Drug: HMW-HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerolized administration b.i.d.
Trial: NCT01477983
Drug: Antiarrhythmic drug (AAD)
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
Trial: NCT01957930
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
Trial: NCT03840538
Drug: Probiotic Product - Cap
RxNorm normalized name: Rezyst Probiotic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
Trial: NCT03627845
Drug: PHP-303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug
Trial: NCT04507659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning: 1\*75mg simulated tablet, 2\*50mg simulated tablets; Evening: 1\*75mg simulated tablet, 2\*50mg simulated tablets.
Trial: NCT00000925
Drug: Optimune oral nutritional supplement
RxNorm normalized name: Optimmune
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02603003
Drug: JinFuKang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po.tid.30ml
Trial: NCT02920385
Drug: SNAC
RxNorm normalized name: Glucerna Snack Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily alone or together with levothyroxine or semaglutide
Trial: NCT00857454
Drug: Testosterone MD-Lotion
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg to 120 mg administered topically once daily for 60 days
Trial: NCT00077077
Drug: DJ-927
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00077077
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00755313
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00755313
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02300103
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily
Trial: NCT00033917
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an anti-inflammatory drug
Trial: NCT00033917
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline
Trial: NCT01796171
Drug: 15 MBq/kg Betalutin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01796171
Drug: 20 MBq/kg Betalutin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02920385
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration alone or together with SNAC or oral semaglutide
Trial: NCT01796171
Drug: 12.5 mBq/kg Betalutin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01515891
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).
Trial: NCT03692663
Drug: TABP EIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
Trial: NCT00060346
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes.
Trial: NCT00060346
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation.
Trial: NCT00211263
Drug: mood stabilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00272909
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV infusion over a period of up to 72 hours of placebo.
Trial: NCT02955641
Drug: Nepafenac 0.1%
RxNorm normalized name: NEPAFENAC 0.1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four drops a day for four days after LPI treatment
Trial: NCT02920385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily together with semaglutide
Trial: NCT00893724
Drug: Neutral pills with no medicinal effect
RxNorm normalized name: Phospha 250 Neutral Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral pills with no medicinal effect